메뉴 건너뛰기




Volumn 32, Issue 4, 2007, Pages 185-196

Bioavailability file: Valsartan

Author keywords

Angiotensin ii receptor inhibitors; Bioavailability; Hypertension; Pharmacokinetics; Valsartan

Indexed keywords


EID: 79959567422     PISSN: 13004182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (58)

References (95)
  • 1
    • 0028798304 scopus 로고
    • Goals of antihypertensive therapy
    • McVeigh GE, Flack J, Grimm R. Goals of antihypertensive therapy. Drugs 49(2): 161-175, 1995.
    • (1995) Drugs , vol.49 , Issue.2 , pp. 161-175
    • McVeigh, G.E.1    Flack, J.2    Grimm, R.3
  • 3
    • 0030750293 scopus 로고    scopus 로고
    • Valsartan. A review of its pharmacology and therapeutic use in essential hypertension
    • Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 54(2): 299-311, 1997. (Pubitemid 27361837)
    • (1997) Drugs , vol.54 , Issue.2 , pp. 299-311
    • Markham, A.1    Goa, K.L.2
  • 5
    • 0030979588 scopus 로고    scopus 로고
    • Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
    • DOI 10.1007/s002280050259
    • Flesch G, Lloyd P, Müller PH. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 52: 115-120, 1997. (Pubitemid 27239595)
    • (1997) European Journal of Clinical Pharmacology , vol.52 , Issue.2 , pp. 115-120
    • Flesch, G.1    Muller, P.2    Lloyd, P.3
  • 7
    • 0029969837 scopus 로고    scopus 로고
    • The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension
    • DOI 10.1016/S0149-2918(96)80040-3
    • Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, Firzsimmons S. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 18(5): 797-810, 1996. (Pubitemid 26397279)
    • (1996) Clinical Therapeutics , vol.18 , Issue.5 , pp. 797-810
    • Oparil, S.1    Dyke, S.2    Harris, F.3    Kief, J.4    James, D.5    Hester, A.6    Fitzsimmons, S.7
  • 9
    • 8244241166 scopus 로고
    • Repeated dose pharmacokinetics of valsartan, a new angiotensin-II antagonist, in healthy subjects
    • Flesch G, Muller Ph, Degen P, Lloyd P, Dieterle W. Repeated dose pharmacokinetics of valsartan, a new angiotensin-II antagonist, in healthy subjects. Eur J Drug Metab Pharmacokinet 18: 256-260, 1993.
    • (1993) Eur J Drug Metab Pharmacokinet , vol.18 , pp. 256-260
    • Flesch, G.1    Muller, Ph.2    Degen, P.3    Lloyd, P.4    Dieterle, W.5
  • 11
    • 55049094798 scopus 로고    scopus 로고
    • Electrochemical behavior of valsartan and its determination in capsules
    • Yan J, Chen L, Chen S. Electrochemical behavior of valsartan and its determination in capsules. Colloids Surf B Biointerfaces 67: 205-209, 2008.
    • (2008) Colloids Surf B Biointerfaces , vol.67 , pp. 205-209
    • Yan, J.1    Chen, L.2    Chen, S.3
  • 13
    • 45449100112 scopus 로고    scopus 로고
    • A simple and efficient synthesis of the valsartan
    • Zhang CX, Zheng GJ, Bi FQ, Li YL. A simple and efficient synthesis of the valsartan. Chin Chem Lett 19: 759-761, 2008.
    • (2008) Chin Chem Lett , vol.19 , pp. 759-761
    • Zhang, C.X.1    Zheng, G.J.2    Bi, F.Q.3    Li, Y.L.4
  • 14
    • 0035468033 scopus 로고    scopus 로고
    • Physicochemical profiling (solubility, permeability and charge state)
    • Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr Top Med Chem 1(4): 277-351, 2001.
    • (2001) Curr Top Med Chem , vol.1 , Issue.4 , pp. 277-351
    • Avdeef, A.1
  • 15
    • 0035292910 scopus 로고    scopus 로고
    • Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract
    • Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract, Adv Drug Del Rev 46: 75-87, 2001.
    • (2001) Adv Drug del Rev , vol.46 , pp. 75-87
    • Horter, D.1    Dressman, J.B.2
  • 16
    • 0034950807 scopus 로고    scopus 로고
    • Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets
    • DOI 10.1016/S0939-6411(01)00147-3, PII S0939641101001473
    • Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Biopharm 52: 75-82, 2001. (Pubitemid 32594790)
    • (2001) European Journal of Pharmaceutics and Biopharmaceutics , vol.52 , Issue.1 , pp. 75-82
    • Takka, S.1    Rajbhandari, S.2    Sakr, A.3
  • 17
    • 17644380257 scopus 로고    scopus 로고
    • Predicting drug disposition via application of BCS: Transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system
    • DOI 10.1007/s11095-004-9004-4
    • Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/ absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22(1): 11-23, 2005. (Pubitemid 40558141)
    • (2005) Pharmaceutical Research , vol.22 , Issue.1 , pp. 11-23
    • Wu, C.-Y.1    Benet, L.Z.2
  • 18
    • 0028948839 scopus 로고
    • A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product and in vivo bioavailability
    • Amidon GL, Lennernas H, Shah VP, Crison J. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product and in vivo bioavailability. Pharm Res 12(3): 413-420, 1995.
    • (1995) Pharm Res , vol.12 , Issue.3 , pp. 413-420
    • Amidon, G.L.1    Lennernas, H.2    Shah, V.P.3    Crison, J.4
  • 19
    • 0037026364 scopus 로고    scopus 로고
    • Comparison of UV- And second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation
    • DOI 10.1016/S0731-7085(02)00360-6, PII S0731708502003606
    • Tatar S, Saglik S. Comparison of UV- and second derivative- spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation. J Pharm Biomed Anal 30(2): 371-375, 2002. (Pubitemid 35013504)
    • (2002) Journal of Pharmaceutical and Biomedical Analysis , vol.30 , Issue.2 , pp. 371-375
    • Tatar, S.1    Salk, S.2
  • 20
    • 0037040623 scopus 로고    scopus 로고
    • Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection
    • DOI 10.1016/S0021-9673(01)01496-0, PII S0021967301014960
    • Gonzalez L, Lopez JA, Alonso RM, Jimenez RM. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr A 949: 49-60, 2002. (Pubitemid 34183413)
    • (2002) Journal of Chromatography A , vol.949 , Issue.1-2 , pp. 49-60
    • Gonzalez, L.1    Lopez, J.A.2    Alonso, R.M.3    Jimenez, R.M.4
  • 21
    • 0031022244 scopus 로고    scopus 로고
    • 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose
    • DOI 10.1080/004982597240767
    • Waldmeier F, Flesch G, Muller P, Winkler T, Kriemler HP, Buhlmayer P, Gasparo MD. Pharmacokinetics, disposition and biotransformation of [ 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 27(1): 59-71, 1997. (Pubitemid 27068372)
    • (1997) Xenobiotica , vol.27 , Issue.1 , pp. 59-71
    • Waldmeier, F.1    Flesch, G.2    Muller, P.3    Winkler, T.4    Kriemler, H.-P.5    Buhlmayer, P.6    De Gasparo, M.7
  • 22
    • 0030575831 scopus 로고    scopus 로고
    • Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester
    • DOI 10.1016/S0378-4347(96)00242-3, PII S0378434796002423
    • Francotte E, Davatz A, Richert P. Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester. J Chromatogr B 686(1): 77-83, 1996. (Pubitemid 26382460)
    • (1996) Journal of Chromatography B: Biomedical Applications , vol.686 , Issue.1 , pp. 77-83
    • Francotte, E.1    Davatz, A.2    Richert, P.3
  • 23
    • 0033168125 scopus 로고    scopus 로고
    • Liquid-liquid extraction in the 96-well plate format with SRM LC/MS quantitative determination of methotrexate and its major metabolite in human plasma
    • DOI 10.1021/ac981294y
    • Steinborner S, Henion J. Liquid-liquid extraction in the 96-well plate format with SRM LC/MS quantitative determination of methotrexate and its major metabolite in human plasma. Anal Chem 71: 2340-2345, 1999. (Pubitemid 29307595)
    • (1999) Analytical Chemistry , vol.71 , Issue.13 , pp. 2340-2345
    • Steinborner, S.1    Henion, J.2
  • 24
    • 0034525745 scopus 로고    scopus 로고
    • A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine
    • Gonzalez L, Alonso RM, Jimenez RM. A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine. Chromatographia 52(11): 735-740, 2000. (Pubitemid 32042686)
    • (2000) Chromatographia , vol.52 , Issue.11-12 , pp. 735-740
    • Gonzalez, L.1    Alonso, R.M.2    Jimenez, R.M.3
  • 26
    • 33745588527 scopus 로고    scopus 로고
    • A comparative, cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs. tablets
    • Perez M, Cardenas W, Ramirez G, Perez M, Restrepo P. A comparative cross-over, double blind, randomized study for bioequivalence assessment between two formulations of valsartan capsules vs. tablets. Colomb Med 37(2): 114-120, 2006. (Pubitemid 43984086)
    • (2006) Colombia Medica , vol.37 , Issue.2 , pp. 114-120
    • Perez, M.1    Cardenas, W.2    Ramirez, G.3    Perez, M.4    Restrepo, P.5
  • 28
    • 33746242339 scopus 로고    scopus 로고
    • Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography
    • Kocyigit-Kaymakcioglu B, Unsalan S, Rollas S. Determination and validation of ketoprofen, pantoprazole and valsartan together in human plasma by high performance liquid chromatography. Pharmazie 61(7): 586-589, 2006. (Pubitemid 44098024)
    • (2006) Pharmazie , vol.61 , Issue.7 , pp. 586-589
    • Kocyigit-Kaymakcoglu, B.1    Unsalan, S.2    Rollas, S.3
  • 29
    • 33750455117 scopus 로고    scopus 로고
    • Optimization via experimental design of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite in human plasma samples
    • DOI 10.1002/jssc.200600093
    • Iriarte G, Ferreiros N, Ibarrondo I, Alonso RM, Maguregi MI, Gonzalez L, Jimenez RM. Optimization via experimental design of an SPE- HPLC- UV-fluorescence method for the determination of valsartan and its metabolite in human plasma samples. J Sep Sci 29(15): 2265-2283, 2006. (Pubitemid 44649640)
    • (2006) Journal of Separation Science , vol.29 , Issue.15 , pp. 2265-2283
    • Iriarte, G.1    Ferreiros, N.2    Ibarrondo, I.3    Alonso, R.M.4    Maguregi, M.I.5    Gonzalez, L.6    Jimenez, R.M.7
  • 30
    • 34848830402 scopus 로고    scopus 로고
    • Biovalidation of an SPE-HPLC-UV-fluorescence method for the determination of Valsartan and its metabolite valeryl-4-hydroxy-valsartan in human plasma
    • DOI 10.1002/jssc.200700033
    • Iriarte G, Ferreiros N, Ibarrondo I, Alonso RM, Maguregui I, Jimenez RM. Biovalidation of an SPEHPLC- UV-fluorescence method for the determination of valsartan and its metabolite valeryl-4-hydroxyvalsartan in human plasma. J Sep Sci 30(14): 2231-2240, 2007. (Pubitemid 47497024)
    • (2007) Journal of Separation Science , vol.30 , Issue.14 , pp. 2231-2240
    • Iriarte, G.1    Ferreiros, N.2    Ibarrondo, I.3    Alonso, R.M.4    Maguregui, M.I.5    Jimenez, R.M.6
  • 31
    • 52449117747 scopus 로고    scopus 로고
    • Rapid quantification of valsartan in human plasma by liquid chromatography using a monolithic column and a fluorescence detection: Application for pharmacokinetic studies
    • Zarghi A, Shafaati A, Fooutan SM, Movahed H. Rapid quantification of valsartan in human plasma by liquid chromatography using a monolithic column and a fluorescence detection: application for pharmacokinetic studies. Sci Pharm 76: 439-450, 2008.
    • (2008) Sci Pharm , vol.76 , pp. 439-450
    • Zarghi, A.1    Shafaati, A.2    Fooutan, S.M.3    Movahed, H.4
  • 32
    • 77953428438 scopus 로고    scopus 로고
    • Validated HPLC method development: The simultaneous analysis of amlodipine and valsartan in samples for liver perfusion studies
    • Çelebier M, Sinan Kaynak MS, Altinöz S, Şahin S. Validated HPLC method development: the simultaneous analysis of amlodipine and valsartan in samples for liver perfusion studies. Hacettepe Univ J Fac Pharm 28(1): 15-30, 2008.
    • (2008) Hacettepe Univ J Fac Pharm , vol.28 , Issue.1 , pp. 15-30
    • Çelebier, M.1    Sinan Kaynak, M.S.2    Altinöz, S.3    Şahin, S.4
  • 33
    • 41049106938 scopus 로고    scopus 로고
    • Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method
    • DOI 10.1002/jssc.200700442
    • Ferreiros N, Iriarte G, Alonso RM, Jimenez RM, Ortiz E. Separation and quantitation of several angiotensin II receptor antagonist drugs in human urine by a SPE-HPLC-DAD method. J Sep Sci 31(4): 667-676, 2008. (Pubitemid 351419571)
    • (2008) Journal of Separation Science , vol.31 , Issue.4 , pp. 667-676
    • Ferreiros, N.1    Iriarte, G.2    Alonso, R.M.3    Jimenez, R.M.4    Ortiz, E.5
  • 34
    • 51849105198 scopus 로고    scopus 로고
    • Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection
    • Piao ZZ, Lee ES, Tran HTT, Beom-Jin Lee BJ. Improved analytical validation and pharmacokinetics of valsartan using HPLC with UV detection. Arch Pharm Res 31(8): 1055-1059, 2008.
    • (2008) Arch Pharm Res , vol.31 , Issue.8 , pp. 1055-1059
    • Piao, Z.Z.1    Lee, E.S.2    Tran, H.T.T.3    Beom-Jin Lee, B.J.4
  • 35
    • 52149120600 scopus 로고    scopus 로고
    • Simultaneous determination of valsartan and hydrochlorothiazide in tablets by RP-HPLC
    • Tian DF, Tian XL, Tian T, Wang ZY, Mo FK. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by RP-HPLC. Ind J Pharm Sci 70: 372-374, 2008.
    • (2008) Ind J Pharm Sci , vol.70 , pp. 372-374
    • Tian, D.F.1    Tian, X.L.2    Tian, T.3    Wang, Z.Y.4    Mo, F.K.5
  • 36
    • 0031932550 scopus 로고    scopus 로고
    • 1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats
    • DOI 10.1016/S0731-7085(97)00128-3, PII S0731708597001283
    • Soldner A, Spahn-Langguth H, Mutschler E. HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP 3174 in biological material of humans and rats. J Pharm Biomed Anal 16: 863-873, 1998. (Pubitemid 28097414)
    • (1998) Journal of Pharmaceutical and Biomedical Analysis , vol.16 , Issue.5 , pp. 863-873
    • Soldner, A.1    Spahn-Langguth, H.2    Mutschler, E.3
  • 37
    • 0344431303 scopus 로고    scopus 로고
    • Determination of SK and F 108566 (Teveten(R)) in human plasma by reversed-phase high-performance liquid chromatography
    • DOI 10.1016/S0378-4347(97)00598-7, PII S0378434797005987
    • Lundberg DE, Person CR, Knox S, Cyronak MJ. Determination of SK&F 108566 (Teveten) in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B 707: 328-333, 1998. (Pubitemid 28198072)
    • (1998) Journal of Chromatography B: Biomedical Applications , vol.707 , Issue.1-2 , pp. 328-333
    • Lundberg Jr., D.E.1    Renee, P.C.2    Knox, S.3    Cyronak, M.J.4
  • 38
    • 0029781981 scopus 로고    scopus 로고
    • Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization
    • DOI 10.1002/(SICI)1096-9888(199608)31:8<873::AID-JMS368>3.0.CO;2-J
    • Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization. J Mass Spectrom 31: 873-878, 1996. (Pubitemid 26258965)
    • (1996) Journal of Mass Spectrometry , vol.31 , Issue.8 , pp. 873-878
    • Kondo, T.1    Yoshida, K.2    Yoshimura, Y.3    Motohashi, M.4    Tanayama, S.5
  • 39
    • 0035816463 scopus 로고    scopus 로고
    • Experimental design methodologies to optimise the spectrofluorimetric determination of Losartan and Valsartan in human urine
    • DOI 10.1016/S0039-9140(01)00379-4, PII S0039914001003794
    • Cagigal E, Gonzalez L, Alonso RM, Jimenez RM. Experimental design methodologies to optimise the spectrofluorimetric determination of Losartan and Valsartan in human urine. Talanta 54: 1121-1133, 2001. (Pubitemid 32607144)
    • (2001) Talanta , vol.54 , Issue.6 , pp. 1121-1133
    • Cagigal, E.1    Gonzalez, L.2    Alonso, R.M.3    Jimenez, R.M.4
  • 40
    • 33947382605 scopus 로고    scopus 로고
    • Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatography-tandem mass spectrometry
    • DOI 10.1016/j.jpba.2006.12.030, PII S0731708506008351
    • Koseki N, Kawashita H, Hara H, Niina M, Tanaka M, Kawai R, Nagae Y, Masuda N. Development and validation of a method for quantitative determination of valsartan in human plasma by liquid chromatographytandem mass spectrometry. J Pharm Biomed Anal 43: 1769-1774, 2007. (Pubitemid 46453072)
    • (2007) Journal of Pharmaceutical and Biomedical Analysis , vol.43 , Issue.5 , pp. 1769-1774
    • Koseki, N.1    Kawashita, H.2    Hara, H.3    Niina, M.4    Tanaka, M.5    Kawai, R.6    Nagae, Y.7    Masuda, N.8
  • 41
    • 34848835442 scopus 로고    scopus 로고
    • Simultaneous determination of fixed dose combination of nebivolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study
    • DOI 10.1016/j.jchromb.2007.08.016, PII S1570023207005867
    • Selvan PS, Gowda V, Mandal U, Solomon WDS, Pal TK. Simultaneous determination of fixed dose combination of nevobiolol and valsartan in human plasma by liquid chromatographic-tandem mass spectrometry and its application to pharmacokinetic study. J Chromatogr B 858: 143-150, 2007. (Pubitemid 47513603)
    • (2007) Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences , vol.858 , Issue.1-2 , pp. 143-150
    • Selvan, P.S.1    Gowda, K.V.2    Mandal, U.3    Solomon, W.D.S.4    Pal, T.K.5
  • 42
    • 62249174362 scopus 로고    scopus 로고
    • Direct analysis of valsartan or candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry
    • Levi M, Grégoire Wuerzner G, Ezan E, Pruvost A. Direct analysis of valsartan or candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry. J Chromatogr B 877(10): 919-926, 2009.
    • (2009) J Chromatogr B , vol.877 , Issue.10 , pp. 919-926
    • Levi, M.1    Grégoire Wuerzner, G.2    Ezan, E.3    Pruvost, A.4
  • 43
    • 59049089752 scopus 로고    scopus 로고
    • Recent development in derivative ultraviolet/visible absorption spectrophotometry
    • Rojas FS, Ojeda CB. Recent development in derivative ultraviolet/visible absorption spectrophotometry. Anal Chim Acta 635: 22-44, 2009.
    • (2009) Anal Chim Acta , vol.635 , pp. 22-44
    • Rojas, F.S.1    Ojeda, C.B.2
  • 44
    • 0033863645 scopus 로고    scopus 로고
    • Simultaneous determination of valsartan and hydrochlorothiazide in tablets by high-performance liquid chromatography
    • Carlucci G, Carlo V, Mazzeo P. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by high-performance liquid chromatography. Anal Lett 33(12): 2491-2500, 2000.
    • (2000) Anal Lett , vol.33 , Issue.12 , pp. 2491-2500
    • Carlucci, G.1    Carlo, V.2    Mazzeo, P.3
  • 45
    • 0035001665 scopus 로고    scopus 로고
    • Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC
    • DOI 10.1016/S0731-7085(01)00394-6, PII S0731708501003946
    • Satana E, Altinay S, Goger NG, Ozkan SA, Senturk Z. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J Pharm Biomed Anal 25(5): 1009-1013, 2001. (Pubitemid 32488968)
    • (2001) Journal of Pharmaceutical and Biomedical Analysis , vol.25 , Issue.5-6 , pp. 1009-1013
    • Satana, E.1    Altinay, S.2    Goger, N.G.3    Ozkan, S.A.4    Senturk, Z.5
  • 46
    • 0037467027 scopus 로고    scopus 로고
    • Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis
    • DOI 10.1016/S0731-7085(02)00643-X, PII S073170850200643X
    • Hillaert S, Van den Bossche W. Simultaneous determination of hydrochlorothiazide and several angiotensin-II-receptor antagonists by capillary electrophoresis. J Pharm Biomed Anal 31(2): 329-339, 2003. (Pubitemid 36254815)
    • (2003) Journal of Pharmaceutical and Biomedical Analysis , vol.31 , Issue.2 , pp. 329-339
    • Hillaert, S.1    Van Den, B.W.2
  • 47
    • 77954612609 scopus 로고    scopus 로고
    • Stability indicating RP-HPLC method for simultaneous estimation of valsartan and amlodipine in capsule formulation
    • Chitlange SS, Bagri K, Sakarkar DM. Stability indicating RP-HPLC method for simultaneous estimation of valsartan and amlodipine in capsule formulation. Asian J Research Chem 1(1): 15-18, 2008.
    • (2008) Asian J Research Chem , vol.1 , Issue.1 , pp. 15-18
    • Chitlange, S.S.1    Bagri, K.2    Sakarkar, D.M.3
  • 48
    • 34447109035 scopus 로고    scopus 로고
    • Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension
    • DOI 10.1016/j.clinthera.2007.03.018, PII S0149291807001002
    • Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R. Two multicenter, 8- week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 29(4): 563-580, 2007. (Pubitemid 47028551)
    • (2007) Clinical Therapeutics , vol.29 , Issue.4 , pp. 563-580
    • Philipp, T.1    Smith, T.R.2    Glazer, R.3    Wernsing, M.4    Yen, J.5    Jin, J.6    Schneider, H.7    Pospiech, R.8
  • 49
    • 0037667643 scopus 로고    scopus 로고
    • Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation
    • Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 24(3): 261-271, 2003. (Pubitemid 36733542)
    • (2003) Endocrine Reviews , vol.24 , Issue.3 , pp. 261-271
    • Carey, R.M.1    Siragy, H.M.2
  • 50
    • 63749129568 scopus 로고    scopus 로고
    • 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults
    • Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol 53(15): 1343-1382, 2009.
    • (2009) J Am Coll Cardiol , vol.53 , Issue.15 , pp. 1343-1382
    • Hunt, S.A.1    Abraham, W.T.2    Chin, M.H.3    Feldman, A.M.4    Francis, G.S.5
  • 51
    • 61849183176 scopus 로고    scopus 로고
    • Heart failure
    • Krum H, Abraham WT. Heart failure. Lancet 373: 941-955, 2009.
    • (2009) Lancet , vol.373 , pp. 941-955
    • Krum, H.1    Abraham, W.T.2
  • 54
    • 0029024577 scopus 로고
    • Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991
    • Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 26(1): 60-69, 1995.
    • (1995) Hypertension , vol.26 , Issue.1 , pp. 60-69
    • Burt, V.L.1    Cutler, J.A.2    Higgins, M.3    Horan, M.J.4    Labarthe, D.5    Whelton, P.6    Brown, C.7    Roccella, E.J.8
  • 56
    • 0029133769 scopus 로고
    • Use of angiotensin II antagonists in human heart failure: Function of the subtype 1 receptor
    • Zagrosek VR, Neuss M, Holzmeister J, Fleck E. Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor. J Hypertens 13(1): 63-71, 1995.
    • (1995) J Hypertens , vol.13 , Issue.1 , pp. 63-71
    • Zagrosek, V.R.1    Neuss, M.2    Holzmeister, J.3    Fleck, E.4
  • 57
    • 0029943358 scopus 로고    scopus 로고
    • Current drug treatment and treatment patterns with antihypertensive drugs
    • Freis ED, Papademetriou V. Current drug treatment and treatment patterns with antihypertensive drugs. Drugs 52(1): 1-16, 1996. (Pubitemid 26193489)
    • (1996) Drugs , vol.52 , Issue.1 , pp. 1-16
    • Freis, E.D.1    Papademetriou, V.2
  • 58
    • 0030716908 scopus 로고    scopus 로고
    • Do we need angiotensin II antagonists to treat hypertensive patients?
    • Menard J, Chatellier G, Azizi M. Do we need angiotensin II antagonists to treat hypertensive patients? J Hum Hypertens 11(2): 1-7, 1997.
    • (1997) J Hum Hypertens , vol.11 , Issue.2 , pp. 1-7
    • Menard, J.1    Chatellier, G.2    Azizi, M.3
  • 59
    • 0034912836 scopus 로고    scopus 로고
    • Angiotensin II subtype 1 receptor blockers and renal function
    • Toto R. Angiotensin II subtype 1 receptor blockers and renal function. Arch Intern Med 161: 1492-1499, 2001. (Pubitemid 32679561)
    • (2001) Archives of Internal Medicine , vol.161 , Issue.12 , pp. 1492-1499
    • Toto, R.1
  • 60
    • 0036828691 scopus 로고    scopus 로고
    • Lessons learned from the Valsartan- Heart Failure Trial (Val-HeFT): Angiotensin receptor blockers in heart failure
    • DOI 10.1016/S0002-9149(02)02667-X, PII S000291490202667X
    • Cohn J. Lessons learned from the valsartan-heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Am J Cardiol 90: 992-993, 2002. (Pubitemid 35232624)
    • (2002) American Journal of Cardiology , vol.90 , Issue.9 , pp. 992-993
    • Cohn, J.N.1
  • 61
    • 34548542222 scopus 로고    scopus 로고
    • Rationale for Combining Blockers of the Renin-Angiotensin System
    • DOI 10.1016/j.semnephrol.2007.07.002, PII S0270929507000873, Hypertension and the kidney: New Avenues for an Improved Management of Hypertension in Renal Diseases
    • Azizi M, Wuerzner G. Rationale for combining blockers of the renin-angiotensin system. Semin Nephrol 27(5): 544-554, 2007. (Pubitemid 47381469)
    • (2007) Seminars in Nephrology , vol.27 , Issue.5 , pp. 544-554
    • Azizi, M.1    Wuerzner, G.2
  • 62
    • 0033069767 scopus 로고    scopus 로고
    • Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH)
    • Guidelines Subcommittee of the World Health Organization-International Society of Hypertension (WHO-ISH). J Hypertens 17: 151-183, 1999.
    • (1999) J Hypertens , vol.17 , pp. 151-183
  • 63
    • 45149087687 scopus 로고    scopus 로고
    • Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: A prospective, randomized, open-label, blinded end-point trial
    • DOI 10.1016/j.clinthera.2008.01.012, PII S014929180800060X
    • Hermida RC, Ayala DE, Khder Y, Calvo C. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial. Clin Ther 30(1): 108-120, 2008. (Pubitemid 351834726)
    • (2008) Clinical Therapeutics , vol.30 , Issue.1 , pp. 108-120
    • Hermida, R.C.1    Ayala, D.E.2    Khder, Y.3    Calvo, C.4
  • 64
    • 55949116516 scopus 로고    scopus 로고
    • Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: A multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study
    • Rump LC, Baranova E, Okopien B, Weisskopf M, Kandra A, Ferber P. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study. Clin Ther 30(10): 1782-1793, 2008.
    • (2008) Clin Ther , vol.30 , Issue.10 , pp. 1782-1793
    • Rump, L.C.1    Baranova, E.2    Okopien, B.3    Weisskopf, M.4    Kandra, A.5    Ferber, P.6
  • 65
    • 0032802509 scopus 로고    scopus 로고
    • Clinical advantage of valsartan
    • McInnes GT. Clinical advantage of valsartan. Cardiology 91 (Suppl 1): 14-18, 1999. (Pubitemid 29371542)
    • (1999) Cardiology , vol.91 , Issue.SUPPL. 1 , pp. 14-18
    • McInnes, G.T.1
  • 67
    • 0030814394 scopus 로고    scopus 로고
    • Valsartan, a new angiotensin II antagonist: Antihypertensive effects over 24 hours
    • DOI 10.1016/S0149-2918(97)80129-4
    • Neutel J, Weber M, Pool J, Smith D, Fitzsimmons S, Chiang YT, Gatliq M. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 19(3): 447-458, 1997. (Pubitemid 27292598)
    • (1997) Clinical Therapeutics , vol.19 , Issue.3 , pp. 447-458
    • Neutel, J.1    Weber, M.2    Pool, J.3    Smith, D.4    Fitzsimmons, S.5    Chiang, Y.-T.6    Gatlin, M.7
  • 68
    • 0032418657 scopus 로고    scopus 로고
    • Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker
    • DOI 10.1016/S0149-2918(98)80107-0
    • Pool J, Oparil S, Hedner T, Glazer R, Oddou-Stock P, Hester A. Dose-responsive antihypertensive efficacy of valsartan, a new angiotensin II-receptor blocker. Clin Ther 20(6): 1106-1114, 1998. (Pubitemid 29058413)
    • (1998) Clinical Therapeutics , vol.20 , Issue.6 , pp. 1106-1114
    • Pool, J.1    Oparil, S.2    Hedner, T.3    Glazer, R.4    Oddou-Stock, P.5    Hester, A.6
  • 69
    • 0041331792 scopus 로고    scopus 로고
    • Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects
    • DOI 10.1161/01.HYP.0000084855.32823.DA
    • Hermida RC, Calvo C, Ayala DE, Domínguez MJ, Covelo M, Fernández JR, Mojón A, López JE. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension 42: 283-290, 2003. (Pubitemid 37093474)
    • (2003) Hypertension , vol.42 , Issue.3 , pp. 283-290
    • Hermida, R.C.1    Calvo, C.2    Ayala, D.E.3    Dominguez, M.J.4    Covelo, M.5    Fernandez, J.R.6    Mojon, A.7    Lopez, J.E.8
  • 70
    • 2342465497 scopus 로고    scopus 로고
    • Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both
    • DOI 10.1016/S0149-2918(04)90049-5
    • Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther 26(4): 460-472, 2004. (Pubitemid 38586448)
    • (2004) Clinical Therapeutics , vol.26 , Issue.4 , pp. 460-472
    • Verdecchia, P.1    Angeli, F.2
  • 72
    • 0033950686 scopus 로고    scopus 로고
    • Newly emerging pharmacologic differences in angiotensin II receptor blockers
    • Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 13: 18-24, 2000.
    • (2000) Am J Hypertens , vol.13 , pp. 18-24
    • Oparil, S.1
  • 73
    • 2142643146 scopus 로고    scopus 로고
    • Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension
    • DOI 10.1097/00004872-200404000-00028
    • Calvo C, Hermida RC, Ayala DE, Luis M, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 22: 837-846, 2004. (Pubitemid 38543577)
    • (2004) Journal of Hypertension , vol.22 , Issue.4 , pp. 837-846
    • Calvo, C.1    Hermida, R.C.2    Ayala, D.E.3    Ruilope, L.M.4
  • 74
    • 0036384291 scopus 로고
    • Valsartan/hydrochlorothiazide: A review of its pharmacology, therapeutic efficacy and place in the management of hypertension
    • Wellington K, Faulds DM. Valsartan/ hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 62(13): 1983-2005, 2002.
    • (1983) Drugs , vol.62 , Issue.13 , pp. 2002
    • Wellington, K.1    Faulds, D.M.2
  • 75
    • 34447253750 scopus 로고    scopus 로고
    • Effects of Valsartan Alone Versus Valsartan/Simvastatin Combination on Ambulatory Blood Pressure, C-Reactive Protein, Lipoproteins, and Monocyte Chemoattractant Protein-1 in Patients with Hyperlipidemia and Hypertension
    • DOI 10.1016/j.amjcard.2007.02.085, PII S0002914907007102
    • Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott MF, Kariisa M, Pitt B. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 100: 222-226, 2007. (Pubitemid 47041985)
    • (2007) American Journal of Cardiology , vol.100 , Issue.2 , pp. 222-226
    • Rajagopalan, S.1    Zannad, F.2    Radauceanu, A.3    Glazer, R.4    Jia, Y.5    Prescott, M.F.6    Kariisa, M.7    Pitt, B.8
  • 77
    • 34447521458 scopus 로고    scopus 로고
    • Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
    • DOI 10.1016/S0140-6736(07)61124-6, PII S0140673607611246
    • Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370: 221-229, 2007. (Pubitemid 47069535)
    • (2007) Lancet , vol.370 , Issue.9583 , pp. 221-229
    • Oparil, S.1    Yarows, S.A.2    Patel, S.3    Fang, H.4    Zhang, J.5    Satlin, A.6
  • 78
    • 34247471686 scopus 로고    scopus 로고
    • Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension
    • DOI 10.1016/j.clinthera.2007.02.003, PII S0149291807000446
    • Poldermans D, Glazer R, Karagiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 29(2): 279-289, 2007. (Pubitemid 46661857)
    • (2007) Clinical Therapeutics , vol.29 , Issue.2 , pp. 279-289
    • Poldermans, D.1    Glazes, R.2    Kargiannis, S.3    Wernsing, M.4    Kaczor, J.5    Chiang, Y.T.6    Yen, J.7    Gamboa, R.8    Fomina, I.9
  • 79
    • 38949199468 scopus 로고    scopus 로고
    • Amlodipine/valsartan: Fixed-dose combination in hypertension
    • DOI 10.2165/00003495-200868030-00008
    • Plosker GL, Robinson DM. Amlodipine/valsartan: fixed-dose combination in hypertension. Drugs 68(3): 373-381, 2008. (Pubitemid 351225813)
    • (2008) Drugs , vol.68 , Issue.3 , pp. 373-381
    • Plosker, G.L.1    Robinson, D.M.2
  • 80
    • 0347405331 scopus 로고    scopus 로고
    • Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension
    • Ke YS, Tao YY, Yang H, Yu GH. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension. Acta Pharmacol Sin 24(4): 337-341, 2003. (Pubitemid 36402199)
    • (2003) Acta Pharmacologica Sinica , vol.24 , Issue.4 , pp. 337-341
    • Ke, Y.-S.1    Tao, Y.-Y.2    Yang, H.3    Yu, G.-H.4
  • 81
    • 24344498223 scopus 로고    scopus 로고
    • Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: An 8-week, randomized, double-blind, parallel-group trial
    • DOI 10.1016/j.clinthera.2005.07.010, PII S0149291805001335
    • Lacourciere Y, Poirier L, Hebert D, Assouline L, Stolt P, Rehel B, Khder Y. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther 27(7): 1013-1021, 2005. (Pubitemid 41262459)
    • (2005) Clinical Therapeutics , vol.27 , Issue.7 , pp. 1013-1021
    • Lacourciere, Y.1    Poirier, L.2    Hebert, D.3    Assouline, L.4    Stolt, P.5    Rehel, B.6    Khder, Y.7
  • 83
    • 0034878670 scopus 로고    scopus 로고
    • Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: Data from a multicenter, randomized, double-blind, 12-week trial
    • DOI 10.1016/S0149-2918(01)80099-0
    • Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. Clin Ther 23(8): 1166-1179, 2001. (Pubitemid 32804112)
    • (2001) Clinical Therapeutics , vol.23 , Issue.8 , pp. 1166-1179
    • Elliott, W.J.1    Calhoun, D.A.2    DeLucca, P.T.3    Gazdick, L.P.4    Kerns, D.E.5    Zeldin, R.K.6
  • 85
    • 0033919444 scopus 로고    scopus 로고
    • Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan
    • Shetty SS, Delgrande D. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan. J Pharm Exp Ther 294(1): 179-186, 2000. (Pubitemid 30434685)
    • (2000) Journal of Pharmacology and Experimental Therapeutics , vol.294 , Issue.1 , pp. 179-186
    • Shetty, S.S.1    Delgrande, D.2
  • 86
    • 0033749162 scopus 로고    scopus 로고
    • Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: A randomized, open-label, crossover study
    • Malacco E, Piazza S, Meroni R, Milanesi A. Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: a randomized, open-label, crossover study. Curr Ther Res 61(11): 789-797, 2000.
    • (2000) Curr Ther Res , vol.61 , Issue.11 , pp. 789-797
    • Malacco, E.1    Piazza, S.2    Meroni, R.3    Milanesi, A.4
  • 87
    • 0036157640 scopus 로고    scopus 로고
    • Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring
    • DOI 10.1016/S0011-393X(02)80002-9
    • Fogari R, Mugellini A, Zoppi A, Derosa G, Rinaldi A, Fogari E, Vanasia A, Preti P. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Curr Ther Res 63(1): 1-14, 2002. (Pubitemid 34112219)
    • (2002) Current Therapeutic Research - Clinical and Experimental , vol.63 , Issue.1 , pp. 1-14
    • Fogari, R.1    Mugellini, A.2    Zoppi, A.3    Derosa, G.4    Rinaldi, A.5    Fogari, E.6    Vanasia, A.7    Preti, P.8
  • 88
    • 0742289119 scopus 로고    scopus 로고
    • Angiotensin II receptor antagonist in pregnancy
    • Morville P. Angiotensin II receptor antagonist in pregnancy. J Perinatol 24: 56-57, 2004.
    • (2004) J Perinatol , vol.24 , pp. 56-57
    • Morville, P.1
  • 89
    • 59449102286 scopus 로고    scopus 로고
    • Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals
    • Brambilla G, Martelli A. Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat Res 681: 209-229, 2009.
    • (2009) Mutat Res , vol.681 , pp. 209-229
    • Brambilla, G.1    Martelli, A.2
  • 91
    • 58849159114 scopus 로고    scopus 로고
    • Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension
    • Blumer J, Batisky DL, Wells T, Shi V, Yohay SS, Sunkara G. Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. J Clin Pharmacol 49: 235-241, 2009.
    • (2009) J Clin Pharmacol , vol.49 , pp. 235-241
    • Blumer, J.1    Batisky, D.L.2    Wells, T.3    Shi, V.4    Yohay, S.S.5    Sunkara, G.6
  • 92
    • 0034088314 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension
    • Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 14(1): 73-86, 2000.
    • (2000) J Hum Hypertens , vol.14 , Issue.1 , pp. 73-86
    • Israili, Z.H.1
  • 93
    • 55549110758 scopus 로고    scopus 로고
    • Adverse drug reactions in patients with cardiovascular disease
    • Faulx MD, Francis GS. Adverse drug reactions in patients with cardiovascular disease. Curr Probl Cardiol 33: 703-768, 2008.
    • (2008) Curr Probl Cardiol , vol.33 , pp. 703-768
    • Faulx, M.D.1    Francis, G.S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.